公司资料
Inventiva 股价、新闻与催化剂
- 股票代码:
- IVA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- France and listed in the U
股票表现
3.75 USD (-1.06%)
收盘价
最后更新: 2026年9月17日
855M USD
市值
股价为何变动
截至 2026年9月17日，IVA 下跌 1.06%，收于 $3.75。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Inventiva is a biotechnology company focused on liver disease and fibrotic conditions, especially metabolic and inflammatory pathways. Its story is centered on MASH and related liver biology.
所在地与行业分类
Headquartered in France and listed in the U.S. as an ADR, Inventiva has a global specialty-biopharma profile.
商业模式特征
The company depends on clinical data, dose selection, and the possibility of building a durable liver-disease franchise.
生物医药行业定位
Inventiva is a catalyst-sensitive liver-disease name whose stock reacts strongly to clinical progress.
未来催化剂
- Inventiva’s catalyst is lanifibranor, especially the MASH / liver-disease development path and any follow-up that keeps the program on track. The market will watch whether the asset can continue to support a credible metabolic-liver story.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。